Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion
Eli Lilly and Company announced on March 31 that it will be acquiring Boston- and London-based Centessa Pharmaceuticals. Centessa Pharmaceuticals is a clinical-stage pharmaceutical company developing a new class of drugs for the treatment of excessive daytime sleepiness and other neurological conditions. Centessa’s lead program is cleminorexton, formerly known as ORX750, which is undergoing a phase 2 study for two types of narcolepsy as well as idiopathic hypersomnia. Eli Lilly is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Eli Lilly discovers, develops, manufactures and sells pharmaceutical products worldwide. Its products... Read More »Merck to Buy Terns Pharmaceuticals for $6.7 Billion
Merck & Co., Inc., known as MSD outside the United States and Canada, will acquire Terns Pharmaceuticals Inc. for $53.00 per share in cash for an approximate equity value of $6.7 billion. Terns Pharmaceuticals Inc. is a clinical-stage oncology company based in San Mateo, California. Terns’ lead program, TERN-701, is a highly selective, oral, allosteric BCR:ABL1 inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia. Merck is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. Merck is focused on the discovery, development,... Read More »
Gilead Sciences to Buy Ouro Medicines for $1.68 Billion Upfront
Gilead Sciences has plans to acquire Ouro Medicines based in South San Francisco, California. The transaction, which was announced on March 24, includes an upfront payment of approximately $1.68 billion, along with up to $500 million in milestone-based payments linked to development and regulatory progress. Ouro Medicines is a privately held biotechnology company. Ouro’s lead investigational antibody therapy, OM336, is currently in early-stage development for autoimmune conditions, including hemolytic anemia and Sjogren’s disease. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas... Read More »
GSK Announces Third Acquisition of the Year
GSK announced on February 24 its third acquisition of 2026 with the purchase of 35Pharma Inc., a clinical-stage biopharmaceutical company. The purchase price is $950 million CAD (approximately $693 million USD). Based in Montreal, Canada, 35Pharma develops novel transforming growth factor-beta superfamily therapeutics. 35Pharma’s lead candidate, HS235, is being developed for the treatment of cardiopulmonary diseases with clinical trials initiated in pulmonary arterial hypertension and PH due to heart failure with preserved ejection fraction. GSK Plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in... Read More »
Swiss Rockets AG Acquires Complete Genomics
Swiss Rockets AG, based in Basel, Switzerland, announced on February 23 that it entered into a definitive agreement to acquire Complete Genomics, Inc. Complete Genomics is a leader in whole human genomic sequencing, which is used by research centers to conduct medical research that, in the future, is expected to be used to improve both prevention and treatment of disease. Since its founding in 2005, the company has been at the forefront of high-throughput, cost-effective sequencing innovation, supporting more than 10,900 scientific publications worldwide. Swiss Rockets is a portfolio of biotechnology companies. Its portfolio includes radioligand therapies, small molecules... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
